Author

Christopher L. Moertel

University of MinnesotaORCID 0000-0002-5474-588XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. S. Daba· 1 shared Alex T. LarssoniD· 1 shared Anzar MujeebiD· 1 shared Apoorva Mirji· 1 shared Brandon L. McClellaniD· 1 shared Bryant J. Keller· 1 shared Chaim T. SneidermaniD· 1 shared David A. LargaespadaiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. S. Daba

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumors

Kyle Brandon Williams, Alex T. Larsson, Bryant J. Keller, Katherine E. Chaney, Rory L. Williams, Minu M. Bhunia, Garrett M. Draper, Tyler A. Jubenville, Wendy A. Hudson, Gunda I. Georg, Christopher L. Moertel, Nancy Ratner, David A. Largaespada

This study identifies 23 compounds that selectively kill NF1-deficient Schwann cells and shows their efficacy in vivo, with synergy when combined with Selumetinib.

Molecular Cancer Therapeutics · Oct 1, 2025Peer-reviewedCancer Biology

CD200 depletion in glioma enhances antitumor immunity and induces tumor rejection

Itay Raphael, Anzar Mujeeb, Elisabet Ampudia-Mesias, ReidAnn E. Sever, Brandon L. McClellan, Stephen C. Frederico, Chaim T. Sneiderman, Apoorva Mirji, A. S. Daba, Francisco Puerta-Martinez, Michal Nisnboym, Wilson Barry Edwards, Michael W. Graner, Christopher L. Moertel, Maria Graciela Castro, , Michael R. Olin

This study shows that CD200 depletion in gliomas enhances antitumor immunity and leads to tumor rejection by modulating immune cell activity and cytokine expression.

bioRxiv · Sep 8, 2024 · PreprintImmunology